Japan's Mochida Pharma To Expand Generic, Biosimilar Cancer Business
This article was originally published in PharmAsia News
Executive Summary
Mochida Pharmaceutical plans to expand its generics and biosimilars lines with an eye on building a $110.2 million-a-year business over the next three years, a rate double this year's expected earnings.